Actaros
↗London, United Kingdom
Actaros is a specialist strategic consultancy providing medical and clinical leadership to the pharmaceutical, biotechnology, and wider life sciences sectors. The firm focuses on bridging the gap between clinical development and commercialization, helping companies navigate complex regulatory environments and optimize their medical affairs functions.
Founded by Dr. Sheuli Porkess, the consultancy leverages deep expertise in the UK and international pharmaceutical landscapes to advise on clinical trial strategy, medical governance, and stakeholder engagement. Actaros often works with early-stage biotechs to build their medical infrastructure and with established firms on high-level policy and strategic shifts.
CLASSIFICATION
Company Type:CRO
Therapeutic Areas:
Industry:Pharmaceuticals
Sub-Industry:Strategic Consulting & Medical Affairs
SIZE & FINANCIALS
Employees:1-50
Revenue:<$1M
Founded:2021
Ownership:private
Status:operating
FUNDING
Stage:Bootstrapped / Self-funded
PIPELINE
Stage:Commercial
Lead Drug Stage:N/A (Service Provider)
Modalities:Small molecule, Biologics, Cell & Gene Therapy
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Faculty of Pharmaceutical Medicine (FPM), Association of the British Pharmaceutical Industry (ABPI), UK Life Sciences Strategy Groups
COMPETITION
Position:Niche Player
Competitors:Boyds, Scrip Consultancy, PharmaGenesis, Lumanity
LEADERSHIP
Key Executives:
Sheuli Porkess - Founder & Director
Scientific Founders:Dr. Sheuli Porkess
Board Members:Sheuli Porkess
LINKS
Website:actaros.co.uk
LinkedIn:LinkedIn Profile
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Actaros. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.